NCT05301751: A trial that was reported late by Allgenesis Biotherapeutics Inc.
This trial has reported, although it was 283 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05301751 |
|---|---|
| Title | A Multicenter, Open-Labeled, Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients With Diabetic Macular Edema |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 19, 2022 |
| Completion date | Sept. 28, 2023 |
| Required reporting date | Sept. 27, 2024, midnight |
| Actual reporting date | July 8, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 283 |